Results 211 to 220 of about 44,768 (301)

Efficacy and immunogenic effects of Tumor Treating Fields (TTFields) in preclinical models of pancreatic ductal adenocarcinoma, with and without gemcitabine/nab‐paclitaxel

International Journal of Cancer, Volume 158, Issue 12, Page 3091-3100, 15 June 2026.
What's new? Adaptive immune responses are typically limited in pancreatic ductal adenocarcinoma, resulting in minimal efficacy of immune checkpoint inhibitors. Tumor Treating Fields (TTFields) therapy, which uses low‐intensity intermediate‐frequency electric fields to disrupt cancer cell processes, has been approved for certain cancers.
Tal Kan, Tharwat Haj Khalil, Yiftah Barsheshet, Tali Voloshin, Lilach Koren, Bella Koltun, Cfir David, Kerem Wainer‐Katsir, Avital Vorontsova, Boris Brant, Simona Zisman‐Rozen, Hila M. Ene, Roni Frechtel‐Gerzi, Shay Cahal, Anat Klein‐Goldberg, Lena Lifshitz, Efrat Zemer Tov, Mai Shai, Adi Haber, Moshe Giladi, Uri Weinberg, Yoram Palti   +21 more
wiley   +1 more source

High Soluble Tumor Necrosis Factor Receptor 2 in Serum Is Associated With Inferior Overall Survival Across Major Lymphoma Subtypes

American Journal of Hematology, Volume 101, Issue 6, Page 1388-1397, June 2026.
ABSTRACT Soluble tumor necrosis factor receptor 2 (sTNFR2) is a member of the TNF superfamily whose normal bodily distribution is largely limited to low level expression on lymphoid cells. It has emerged as an important inducible receptor that activates a signaling pathway for cancer growth.
Arushi Khurana, Hikaru Hayashi, Bethany Thach, Zhi Zhang Yang, Brianna J. Negaard, James R. Cerhan, Anne J. Novak, Brian K. Link, Thomas M. Habermann, Andrew L. Feldman, Sameer A. Parikh, Susan L. Slager, Stephen M. Ansell, Matthew J. Maurer, Denise L. Faustman   +14 more
wiley   +1 more source

Myeloid-derived suppressor cells (MDSCs) in patients with solid tumors: considerations for granulocyte colony-stimulating factor treatment. [PDF]

Cancer Immunol Immunother, 2018
Pilatova K, Bencsikova B, Demlova R, Valik D, Zdrazilova-Dubska L.   +4 more
europepmc   +1 more source

The Dual Role of Autophagy in Cancer: Mechanisms and Therapeutic Strategies

MedComm – Oncology, Volume 5, Issue 2, June 2026.
Autophagy is a conserved cellular process degrading dysfunctional organelles and protein aggregates to maintain cell homeostasis, and it exhibits context‐dependent duality in cancer. Autophagy functions as a critical tumor‐suppressive mechanism by preventing DNA damage and mutation during tumor initiation.
Xiang‐Zheng Gao, Yuheng Qin, Haoyu Wan, Guang Lu, Han‐Ming Shen   +4 more
wiley   +1 more source

Oxidative Stress in the Tumor Immune Microenvironment: Mechanisms and Therapeutic Perspectives

MedComm – Oncology, Volume 5, Issue 2, June 2026.
Oxidative stress is involved in several key processes in cancer, including redox regulation, DNA damage, post‐translational modifications, transcriptional regulation, epigenetic modifications, metabolic reprogramming, cell death, and immune modulation. These mechanisms collectively influence tumor progression, immune evasion, and therapeutic responses,
Zhen Wang, Bowen Li, Pan Tang, Fanchen Yan, Shuxin Wang, Guiying Leng, Panduo Dawa, Yuansi Chen, Yihan Guo, Pan Yang, Yi Li, Siyu Liu, Erdan Dong, Siyuan Qin, Zhoufeng Wang   +14 more
wiley   +1 more source

Tumor‐Resident Mast Cells Facilitated Breast Cancer Progression via Activating Type I Interferon Pathway

MedComm – Oncology, Volume 5, Issue 2, June 2026.
Breast cancer cell‐derived stem cell factor (SCF) activates c‐KIT‐mediated MAPK/ERK signaling in mast cells, inducing IFNB1 production. Mast cell‐derived IFNB1 then engages the IFNAR1‐STAT1 axis in breast cancer cells, activating the Type I interferon pathway to promote tumor stemness and progression.
Siqin Li, Juchuanli Tu, Ruoyi Ding, Xueyan He, Xian Zhang, Mengxue Dong, Fengkai Li, Wen Yi, Yuwei Tao, Wei Ma, Zhijun Dai, Zhenhua Chen, Yuan Wang, Xiongbin Lu, Jian Liu, Suling Liu, Jiahui Xu   +16 more
wiley   +1 more source

Therapeutic application of myeloid-derived suppressor cells (MDSC) in dry eye disease

Purpose : To assess the immunosuppressive functions and therapeutic potential of locally administered MDSC in an established murine model of dry eye disease (DED). Methods : MDSC (CD11b+ Gr-1+ ) were isolated from cultured bone marrow cells via magnetic sorting.
Lee, S, Surico, PL, Singh, RB, Naderi, A, Bhullar, S, Blanco, T, Chen, YH, Dana, R   +7 more
openaire   +1 more source

Targeting Ikaros and Aiolos: Next‐Generation Cereblon E3 Ligase Modulators in MM

European Journal of Haematology, Volume 116, Issue 6, Page 697-708, June 2026.
The graphical abstract illustrates the mechanism of action of cereblon E3 ligase modulators (CELMoDs) in multiple myeloma, highlighting cereblon‐mediated degradation of IKZF1 and IKZF3. Compared with classical immunomodulatory drugs (IMiDs), CELMoDs induce deeper IKZF1/3 depletion, leading to more pronounced suppression of the IRF4–MYC survival axis ...
Maria Eugenia Alvaro, Enrica Antonia Martino, Santino Caserta, Mamdouh Skafi, Antonella Bruzzese, Nicola Amodio, Eugenio Lucia, Virginia Olivito, Caterina Labanca, Francesco Mendicino, Ernesto Vigna, Fortunato Morabito, Massimo Gentile   +12 more
wiley   +1 more source

Myeloid derived suppressor cells and their role in diseases [PDF]

, 2013
Apostolopoulos, Vasso, Fuchsberger, M, Kong, James, Plebanski, M, Xiang, SD   +4 more
core   +1 more source

Vaginal Microbiota and Ovarian Cancer: A New Frontier in Immunomodulation and Diagnosis

Immunology, Volume 178, Issue 2, Page 209-217, June 2026.
Microbial imbalance, dysbiosis, plays a role in ovarian carcinogenesis by interacting with the immune system and altering inflammatory pathways, notably Th17 pathways. In contrast, eubiosis, characterised by Lactobacillus dominance, protects against infections and maintains hormone metabolism.
Wafa Babay, Mariem Garci, Ahmed Baligh Laaribi, Nabil Mathlouthi, Imene Ouzari   +4 more
wiley   +1 more source